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Like other rare diseases, progress in thymic malignancieshas been slow at best. The literature consists mainly of
single-institution retrospective studies, usually spanning sev-
eral decades. Furthermore, ambiguities in commonly used
terms and poor description of the details of patient selection
and treatment approach further limit the conclusions that can
be reached from these data. There have been few prospective
studies or clinical trials. Although a few centers with expe-
rience in thymic conditions have achieved some recognition,
there is a general sense that because almost no one knows
much about these diseases, it is acceptable for a physician
with very limited experience to do whatever he/she thinks is
best when treating an occasional patient. Persistence of mis-
leading terms such as “benign thymoma,” which are no
longer tenable in the modern era, contributes to this problem.
Progress and understanding in this field will continue to be
limited unless a better way forward is found.
To address this problem, the Foundation for Thymic
Cancer Research (an organization founded by patients and
family members) organized several conferences of people
who have published in this field (in New York [2007] and
Houston [2008]). This culminated in cosponsorship, together
with the National Institutes of Health (NIH), of the first
International Conference on Thymic Malignancies in Be-
thesda in August 2009. During the course of these meetings,
it was clear that real progress would require creation of a
scientific infrastructure to foster collaborative research. The
concept of a scientific organization dedicated to thymic ma-
lignancies and other mediastinal diseases was born in late
2008. Preliminary work during the first half of 2009 led to the
implementation of a transitional structure in the conference
held in August 2009 at the NIH. The name International
Thymic Malignancies Interest Group (ITMIG) was chosen.
The work of the transitional workgroups led to the initiation
of ITMIG as a formal organization at the first ITMIG con-
ference in New York on May 5 and 6, 2010. This conference
generated much enthusiasm and excitement and was attended
by 117 participants from more than 20 countries and all
continents except Africa and Antarctica.
Many professional organizations have come forward to
support the creation of ITMIG, including the American As-
sociation for Thoracic Surgery, the European Association of
Cardiothoracic Surgeons, the European Society for Myasthe-
nia Gravis, the European Society of Thoracic Surgeons, the
Fleischner Society, the General Thoracic Surgical Club,
the International Association for the Study of Lung Cancer,
the Japanese Association for Research on the Thymus, the
Japanese Association for Thoracic Surgery, the mediastinal
workgroup of the European Society of Pathologists, the
Myasthenia Gravis Foundation of America, the Society of
Thoracic Radiologists, the Society of Thoracic Surgeons, and
the Thoracic Oncology Network of the American College of
Chest Physicians.
The mission of ITMIG is to promote the advancement
of clinical and basic science pertaining to thymic malignan-
cies and related mediastinal conditions. ITMIG is an aca-
demic organization that provides structure, organization, and
scientific rigor to research in these diseases. The primary
goals of ITMIG are to provide infrastructure for international
collaboration, promote a scientifically based approach, and
facilitate dissemination of knowledge about thymic malig-
nancies and other mediastinal diseases. ITMIG is a registered
not-for-profit organization. In May 2010, ITMIG had approx-
imately 250 members from North and South America, Eu-
rope, Asia, and Australia. It is a multispecialty organization,
involving thoracic surgeons, medical and radiation oncolo-
gists, pulmonologists, radiologists, pathologists, neurologists,
and basic science researchers. In May 2010, the first Presi-
dent, Vice President, Secretary, Treasurer, and councilors
were elected for 2-year terms on the steering committee. The
original transitional workgroups have morphed into standing
committees and workgroups and are implementing the initial
ITMIG projects.
INITIAL PROJECTS
A cornerstone of making progress is the ability to
collaborate throughout the world. ITMIG has reached out to
other individuals and organizations associated with thymic
diseases and has been met with an enthusiastic willingness to
build a mutual collaborative relationship. Thymic focus
groups exist in Japan and Europe, and ITMIG supports their
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efforts. These groups also see value in developing a wider
interaction through ITMIG. The ITMIG meeting and leader-
ship underscores that this is truly an international effort. The
collaborative spirit that permeates the organization is a major
initial accomplishment, paving the way for the other initia-
tives of the organization.
Promotion of the exchange of scientific data is a major
goal of ITMIG. The ITMIG 2010 meeting featured 46 ac-
cepted abstracts. These proved to be high-quality studies,
involving a wide range of research approaches and many
novel approaches. The seven abstracts selected for oral pre-
sentation included topics, such as molecular biology, new
surgical techniques, new chemotherapy agents, novel multi-
modality approaches (photodynamic therapy, heated intraop-
erative chemotherapy), and epidemiologic and radiologic
studies. The ability to present data to a concentrated group of
interested individuals was very valuable. The 2010 ITMIG
meeting was clearly successful in generating scientific ex-
change, stimulation of new ideas, promotion of networking,
and development of new collaborations.
A prerequisite to collaboration is to establish a clear
consistent language. Many terms are ambiguously defined or
completely lacking in the definition of major details. Once
one looks below the surface, it becomes clear that how things
have been interpreted in different centers sometimes differs
significantly. Several workgroups have achieved a consensus
regarding definition of terms and standardization of some
processes. The first major report “Standard Outcome Mea-
sures for Thymic Malignancies” was formally endorsed by
ITMIG and is under review for publication in the Journal of
Thoracic Oncology. Other projects involve standard operat-
ing procedures regarding handling and reporting of surgical
specimens, biopsy specimens, radiotherapy, and reporting of
histologic findings. Some of these projects are nearly com-
plete while others are beginning. However, it has become
clear that ITMIG has the ability to develop very broad
consensus among those active and interested in thymic ma-
lignancies about important details for which previously there
has been little consistency.
A major project is the creation of an international
database. Preliminary work to develop standard data elements
and a platform for a web-based database had been accom-
plished. The remainder of 2010 will be devoted to finalizing
the data elements and dictionary and initiating a prospective
database. ITMIG is also exploring what retrospective data are
available and to what extent it can be combined and analyzed.
The International Staging Committee (ISC) of IASLC
has just completed a huge, 10-year effort to scientifically
validate and improve the lung cancer staging system. The ISC
has targeted thymoma for establishment of a scientifically
based staging system for the next edition of the official
staging book. ITMIG and the ISC have established a formal
close relationship to accomplish this task.
Clearly a way forward is to build a collective tissue
resource for molecular biologic investigation. As a first step,
ITMIG has established a virtual tissue bank. Tissues remain
stored at the source institution but are annotated in a consis-
tent fashion on a web-based platform. The structure fosters
collaborative studies between contributing institutions.
Traditional methods of clinical research have major
limitations when applied to rare diseases. The cost of opening
and maintaining studies that only accrue an occasional patient
is an issue, and there are major regulatory and political
difficulties to conduct studies in many different countries.
Furthermore, the traditional system for clinical research ef-
fectively blocks any funding for rare diseases, because phase
III studies in rare diseases never have sufficient background
data to estimate outcomes or sufficient accrual. To move
forward, ITMIG must adopt innovative approaches. The tim-
ing for this is good because statistical tools and research
methods that are applicable to rare diseases have been devel-
oped (e.g., Bayesian research and propensity matching). The
tone for innovative approaches has been set with the expec-
tation that each ITMIG meeting will have a lecture devoted to
educate the members about such approaches.
An innovative approach that is being considered by
ITMIG is a collaborative observational study. Participating
centers would commit to a standardized system of data
collection that will carefully define patient and tumor
characteristics. Patients will then be treated according to
the local routine, but each institution must define and
adhere to (within limits) its treatment approach for partic-
ular cohorts of patients. The differences in treatment
approaches then become an asset, and negotiations to
change local routines to a single approach are avoided.
Using appropriate statistical techniques to manage bias and
differences in patient selection in different centers, likeli-
hood ratios for survival for various approaches can be
generated. In this way, all data on patients treated during
routine care at participating institutions can be used to
build an expanding knowledge base that allows the field to
gradually evolve in a data-driven manner.
Another innovative approach being explored is adapta-
tion of engineering tools developed for complex systems to
thymic malignancies. Such tools have already been success-
fully adapted to more common cancers in a major Cancer
Care Engineering project involving Purdue University, Indi-
ana University, and the Discovery Park Institute. The process
involves developing a knowledge acquisition framework that
allows data from many disparate sources (clinical, laboratory,
epidemiologic, etc.) to be linked together. Application of
sophisticated adaptive modeling tools provides insight into
the implications of new data throughout the system. This can
be used to focus the research efforts strategically and dynam-
ically to the areas that are likely to have the greatest impact.
Because the modeling structure is adaptive, anticipated and
unanticipated changes brought about by progress in any
particular area can be accommodated. The success in other
cancers makes adaptation to a rare disease such as thymoma
very appealing.
PLANNED PROJECTS
Several new initiatives are just beginning to get under-
way. ITMIG plans to develop a series of educational libraries,
available openly on its website, as a resource for physicians
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and caregivers who have limited experience with thymic
malignancies and are searching for help. These will involve
radiology and pathology in the initial phase. Expansion of the
focus of ITMIG to other mediastinal conditions is planned.
Development of research efforts that include immunology,
epidemiology, and outcomes research is also planned. A
particular focus will be the development of reasonable quality
metrics for the clinical care of patients with thymic malig-
nancies. Approaching the issue of wide discrepancies in
knowledge and experience in a constructive manner should
allow this to be to everyone’s benefit.
CONCLUSION
ITMIG was formed in a transitional manner at the first
International Conference on Thymic Malignancies in Be-
thesda in August 2009 and has now become a substantial,
albeit young, official organization. Much progress has been
made in building a foundation for collaborative research. The
next phase is to build on the momentum and implement the
infrastructure that has been developed. Anyone interested in
thymic malignancies or other mediastinal conditions is en-
couraged to visit the website www.itmig.org for further
information or to join and get involved.
APPENDIX: PRESENTATION ABSTRACTS FROM ITMIG MEETING, MAY 5 AND 6, 2010
Prognostic Significance and Reproducibility of Three Histologic
Classifications for Thymic Epithelial Tumors
A.C. Roden,* E.S. Yi,* S.M. Jenkins,† J.L. Donovan,* R.S. Marks,‡ S.D.
Cassivi,§ Y.I. Garces, and M.C. Aubry* *Department of Laboratory
Medicine and Pathology, †Division of Biomedical Statistics and Informatics,
‡Division of Medical Oncology, §Division of General Thoracic Surgery, and
Department of Radiation-Oncology, Mayo Clinic, Rochester, Minnesota
Background: Thymomas can be complicated by invasion, recurrence, me-
tastases, and death. Several histologic classifications have been proposed;
however, their prognostic significance, ability to guide further treatment, and
reproducibility have been controversial.
Design: Medical records from 200 patients with thymoma (1942–2003) were
reviewed. Two pathologists independently classified all cases. If multiple
subtypes exist, predominant and minor components were also recorded.
Statistical analyses were performed.
Results: One hundred four women and 96 men had a median age of 54 years.
The median follow-up was 7.7 years. In 29 patients, recurrence and/or
metastasis occurred. Ten patients died of the disease.
Patients were staged according to Masaoka: I (n  54), II (n  91), III
(n  40), IVa (n  12), and IVb (n  3).
Interobserver agreements were World Health Organization (WHO),  0.518;
Bernatz,  0.486; Suster and Moran,  0.539; Invasion,  0.377.
In the univariate prognostic factor analysis (log-rank test), Masaoka staging and
all three histologic classifications were predictors of recurrence-free survival
(RFS) (p  0.004, all) and overall survival (OS) (p  0.0001, all). Only
Masaoka staging is a predictor of disease-free survival (DFS) (p  0.0001).
Multivariable Cox proportional hazards regression analysis revealed that
Masaoka staging is the best predictor of RFS. All three histologic classifi-
cations are similar in predicting RFS. For OS, Masaoka remains superior to
all histologic classifications except WHO. After adjusting for Masaoka,
surgical resection, superior vena cava syndrome, and additional therapy, no
histologic classification was significantly associated with OS.
Conclusion: In the univariate analysis, Masaoka staging and all three
histologic classifications are predictors of RFS and OS, but only staging
remains a predictor of DFS. Masaoka staging is the strongest predictor for
RFS and OS and superior to the histologic classifications.
Robotic Thymectomy for Thymoma: When
and Why?
J.C. Ru¨ckert,*, M. Swierzy,*, B. Rudolph,†, H. Badakhshi,‡ P. Hein,§ P.
Rogalla, A. Marx,¶ and M. Ismail* Departments of *General, Visceral,
Vascular Thoracic Surgery, †Pathology, ‡Radiation Oncology, and §Radiology,
Charite´ Campus Mitte, Charite´ - Universita¨tsmedizin Berlin, Berlin, Germany;
Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada;
and ¶Reference Center for Thymic and Mediastinal Pathology, Institute of Pathol-
ogy, Universita¨tsmedizin Mannheim, Mannheim, Germany
Objectives: The surgical treatment of thymoma is the essential part of a
multimodal therapy. In most clinics, median sternotomy is still the method of
choice for all stages of thymoma. However, there is an increasing tendency
toward minimally invasive resection of early-stage tumors. Selection criteria
and results of robotic thymectomy for thymoma are presented.
Methods: A prospective study analyzed 30 cases of robotic thymectomy for
thymoma. All patients underwent a preoperative computed tomography scan
of the chest. A standard unilateral three-trocar left-sided technique, with the
da Vinci robotic system, was used. All patients were analyzed for survival
rate, tumor recurrence, and technical aspects of the procedure. For patients
with thymoma and myasthenia gravis, we analyzed the functional improvement
according to the classification of the Myasthenia Gravis Foundation of America.
Furthermore, the histologic findings were also confirmed at an international
reference center for thymic pathology.
Results: Thirty patients (12 females) with a mean age of 54.3 years (range,
13–84 years) were surgically treated between January 2003 and February
2010. Myasthenia gravis was found in 22 patients, and all these patients had
antibodies for AChR. The mean robotic operating time was 178.6 minutes
(range, 75–285 minutes). The mean specimen size was 204  84  26 mm
(range, 110 50 15 to 330 140 50 mm). There were 10 patients with
Masaoka stage I, 19 patients with stage II, and 1 patient with stage III. There
were no postoperative complications. All patients survived without a recur-
rence during a mean follow-up of 24 months (range, 1–86 months).
Conclusion: The selection of robotic surgery depends on symptoms, anatomic
localization, size, comorbidity, radiologic findings, surgical school, and experience of
the surgeon as well as availability of the robotic technology. So far, our data are very
encouraging in terms of survival and clinical advantages, such as cosmetic results,
less morbidity, shorter hospital stay, and better tolerability for elderly as well as
comorbid patients. Clearly, a much longer follow-up and prospective clinical studies
comparing traditional and robotic approaches are needed to establish the robotic
technique as standard routine.
Radical Pleurectomy and Photodynamic Therapy as a Treat-
ment for Stage IVA Thymic Tumors
Y. Hsieh, R. Mick, M. Culligan, K. Cengel, S. Hahn, S. Cowan, and J.S.
Friedberg Departments of Surgery and Radiation Oncology, University of
Pennsylvania, Philadelphia PA
Objective: Treatment of patients with pleural dissemination of thymoma or
thymic carcinoma, Masaoka stage IVA, remains challenging and controversial.
There have been several recent reports detailing the utility of extrapleural
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pneumonectomy as part of a multimodal approach to this disease, but patients
with myasthenia gravis are not generally considered for this aggressive surgical
approach. Photodynamic therapy (PDT) is a light-based cancer treatment that
can be delivered as an intraoperative adjuvant treatment. The objective of this
study was to determine whether PDT and radical pleurectomy could be com-
bined as a lung-sparing treatment for patients with stage IVA thymic tumors.
Methods: Between August 2002 and September 2009, 15 patients with stage
IVA thymoma (10 with myasthenia gravis) and 2 with thymic carcinoma
underwent radical pleurectomy (RP) and intraoperative PDT. The mean age
was 48 years (range, 23–83 years), and 71% enrolled with recurrent disease.
Neoadjuvant treatment included chemotherapy in 71% of patients, radiother-
apy in 47%, and plasmapheresis in 35%. Surgical procedures included RP (5
patients), RP/pericardial resection (two patients), RP/diaphragm resection
(six patients), RP/pericardium and diaphragm resections (three patients), and
palliative debulking (one patient). There were 14 macroscopic complete resec-
tions, 2 partial resections, and 1 intentionally palliative procedure for an intrac-
table malignant effusion. All patients received intraoperative PDT.
Results: There were two 30-day mortalities: one disseminated intravascular
coagulation-related hemorrhage and one pulmonary embolism. At a median
follow-up of 1.4 years, 5 patients have recurred (four local and one distant),
4 patients died, and 13 patients are alive (10 without recurrence). Kaplan-
Meier median recurrence-free survival (RFS) is 2 years, and the 1-year RFS
rate (SE) is 77% (12%). The median overall survival (OS) has not yet
been reached (Fig. 1), and the 1-year OS rate is 74% (12%). Five patients
are long-term survivors at 2 or more years (range, 1.9 to 7.1 years).
Conclusions: We conclude that RP combined with intraoperative PDT is a
treatment option for patients with stage IVA thymic tumors, with 10 of 16
patients treated with curative intent in this series alive and with no evidence
of disease. These results are comparable with those reported by some other
groups in which extrapleural pneumonectomy was performed for debulking
purposes. The role of PDT as an intraoperative adjuvant in this treatment is
that it provides the option of preserving the lung, which in addition to the
obvious benefits provides the option of offering an aggressive surgical option
to patients with myasthenia gravis.
A Phase II Study of Saracatinib (AZD0530), an SRC Inhibitor,
Administered Orally Daily to Patients with Advanced Thymic
Malignancies
Heather A. Wakelee, Matthew Burns, Matthew Gubens, Sarah Barbeau, and
Patrick J. Loehrer Stanford University, Stanford, California; and Indiana
University, Indianapolis, Indiana
Background: Saracatinib (AZD0530) is an orally bioavailable small mole-
cule inhibitor of the Src family of tyrosine kinases. Src and its ligands are
important components of thymocyte development, and it was postulated that
Src pathway crosstalk with thymic stroma made Src a good target in thymic
malignancies. The purpose of the present study was to determine the activity
of saracatinib in patients with previously treated advanced thymic malignan-
cies (ATM) (thymoma and thymic carcinoma [TC]).
Methods: This was a two-institution, two-stage phase II study. Patients with
ATM received AZD0530 (175 mg) orally daily for repeated 28-day cycles.
Response was assessed by RECIST criteria after two cycles (approximately
2 months). An additional computed tomography (CT) scan was obtained
after cycle 1 to evaluate for evidence of pulmonary toxicity.
Results: A total of 21 patients were enrolled at two institutions, 14 with
thymoma and 7 with TC. Two patients were not evaluable for response
because they were receiving less than one cycle (one thymoma and one TC).
Enrolled patients’ age range was 18 to 70 years (11 male and 10 female
patients). The majority of patients were ethnically White, with the remainder
of patients of the following ethnicities: three Asian, one African American,
and one unknown. Three patients remain on study, with the majority
discontinued because of PD. One patient died within 30 days of last
treatment because of PD. Although no pulmonary toxicity was identified on
the prespecified 1-month CT scan, one patient was hospitalized because of
pleural effusions that developed while on therapy. The effusions were not
seen on the CT scan at 1 month but were visible on CT scan and symptomatic
at the 2-month visit. She was discontinued from the trial because of disease
progression, and the pleural effusions responded to local therapy. One patient
had dyspnea while on therapy and was discontinued for this serious adverse
event, without evidence of an effusion or any interstitial infiltrates. No other
significant pulmonary toxicities were reported. One patient each had grade 3
neutropenia (transient) and grade 3 anemia (requiring transfusion). Other
toxicities were grade 1/2 and as expected. As prespecified in the protocol,
after 13 evaluable thymoma patients were enrolled to ensure 12 evaluable
patients, enrollment was suspended to assess activity (Simon two-stage
design). Because none of these patients met a PR by RECIST criteria, accrual
to the study was halted. Eight patients had stable disease beyond first
assessment (two cycles/2 months) (range, 3–7 cycles with three still on
therapy).
Conclusion: Because of lack of clinical activity (no RECIST responses) after
2 months of therapy (date of first assessment) with saracatinib for the first 13
thymoma patients enrolled, the study was terminated as prespecified. Eight of
21 patients had stable disease at 2 months, and three patients remain on
therapy. No unexpected toxicities were seen.
Fifteen Years Experience with Pleural Perfusion Thermochemo-
therapy for Thymic Epithelial Malignancies with Pleural Spread
Alon Yellin and David A. Simansky Sheba Medical Center, Tel Hashomer,
Israel
Objective: The preferred treatment for thymic epithelial malignancies with
pleural spread (TEMPS) is not yet determined. Options vary from observa-
tion, through chemotherapy and/or radiotherapy and/or local resection, to
extrapleural pneumonectomy. Previously, we have shown that resection plus
pleural perfusion thermochemotherapy (PPTCT) is feasible and safe and may
offer a survival benefit. Presently, we analyze the long-term results, com-
paring de novo stage IV-a thymoma (DNIV-a) with thymoma recurring in the
pleura (TRP) and with stage IV-a thymic carcinoma (TC).
Methods: Thirty-one patients with DNIV-a (n 14), TRP (n 12), and TC
(n  5) underwent 39 operations combined with PPTCT using a standard
roller pump and modified heat exchanger with 100 mg/m2 of CDDP in all
patients plus 50 mg of Adriamycin in about half of the patients. Perfusion
lasted 60 minutes at a temperature of 41°C to 43°C. Follow-up was 9 months
to 16 years. Survival was studied by the Kaplan-Meier method. All data were
recorded prospectively.
FIGURE 1. Overall survival of masaoka stage IVA thymic
tumor patients treated with pleurectomy and intraoperative
photodynamic therapy.
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Results: DNIV-a had more females and R0 resections and less type B3 than
TRP. Groups were similar in age, associated myasthenia (45%), Adriamycin
installation, and perfusion temperature. TC included only one female and had
no myasthenia. There was one in-hospital death (d35, 2.5%) in a redo
PPTCT; major (10%) and minor (10%) complication rates were acceptable.
There was no hematological, renal, neurologic, or cardiac morbidity. Late
myasthenic crisis occurred twice. Eight ipsilateral (n  6) and contralateral
(n  2) recurrences were treated with repeat PPTCT that was technically
demanding. All TC patients and one DNIV-a patient died of disease pro-
gression. One patient each succumbed to leukemia, myasthenic complica-
tions, liver failure, and chronic empyema.
The 1-, 3-, 5-, and 10-year survival rates for DNIV-a, TRP, and TC,
respectively, were 86%, 100%, 100%; 83%, 80%, 20%; 82%, 70%, 0% and
unchanged at 10 years (Fig. 2).
Conclusions: In patients with TEMPS, surgery  PPTCT is devoid of toxic
effects; associated with a low mortality rate and acceptable major and minor
morbidity. It offers good locoregional control; excellent long-term outcome
in thymoma, and poor results in TC. Repeated operations with or without
PPTCT may be required but are difficult to perform.
The Pathology and Epidemiology of Thymoma: An Analysis of
2189 Cases from the SEER Database
A.M. Schwartz,* L.E. Kostun,† K. Batich,† and D.E. Henson† *Department
of Pathology, The George Washington University; and †The George Wash-
ington University Cancer Institute, Washington, DC
Introduction: The biology and clinical behavior of thymic tumors are
governed by histomorphometric patterns, tumor grade, and stage. Most
studies use limited data for tumor evaluation and prognosis. We have
investigated the NCI’s Surveillance, Epidemiology, and End Results (SEER)
database to identify demographic and clinical prognostic factors.
Methods: Data were obtained from NCI’s SEER program and include
information from Registry 17 (1973–2006) and Registry 9 (1973–2006).
Cases were compared by linear plots of incidence, age of diagnosis, relative
Kaplan-Meier survival rates, frequency density, and linear and log-log plots
of the age-specific incidence rates. World Health Organization (WHO) types
A, AB, B1, B2, B3, and C were considered. Rates are expressed as number
of cases per 100,000 persons.
Results: Thymomas affect both men and women (M:F  1.2:1). Thymomas
have increased in incidence continuously over 33 years (1973–2006), with a near
doubling in incident rate. Thymic carcinomas (WHO type C) have increased at
a similar rate. Log-log plots of age versus incidence showed near-parallel slopes
of thymic histologic types, suggesting a common pathogenesis for all thymomas.
Frequency density plots showed that all thymomas (low grade, high grade, and
carcinoma) have near-identical distributions. All thymomas seem to have an inci-
dence rate peak in the eighth decade. Relative Kaplan-Meier survival calculations
demonstrated that 5-year survival rates can be stratified into three groups: I, type A,
AB, B1 (85%); II, type B2, B3 (75%); and III, type C (54%).
Conclusions: Thymic tumors are increasing as the age of the population
increases, although there may be other factors generating the increase in
incidence. All thymomas have similar age frequency distributions despite
differences in tumor histologic patterns. Results of survival analysis suggest
that a more limited stratification of tumor histologic patterns would best
define prognostic groups. Except for survival, thymic carcinomas have the
same epidemiologic patterns as other thymic tumors.
Expression of Angiogenesis-Related Biomarkers in Thymic Ep-
ithelial Tumors
M. Marino,* R. Lattanzio,† L. Lauriola,‡ R. Martucci,* S. Sioletic,* E.
Gallo,* G. Palmieri,§ A. Evoli,‡ P. Granone,‡ G. Palestro, R. Chiarle, A.
Barreca, A. Pich, D. Remotti,¶ R. Pisa,¶ M. Martelli,¶ M. Truini,# S.
Ascani,** L. Ruco,†† E.A. Rendina,†† G. Tunesi,‡‡ M. Antimi,§§ M.
Lalle,§§ S. Carlini,* F. Facciolo,* and M. Piantelli† *Regina Elena National
Cancer Institute, Rome; †University of Chieti, Chieti, ‡Catholic University,
Rome; §“Federico II” University, Naples; University of Turin, Turin;
¶S.Camillo-Forlanini Hospital, Rome; #National Cancer Institute, Genua;
**University Medical Center Terni, University of Perugia, Terni; ††S.
Andrea Hospital, University “La Sapienza”, Rome II; ‡‡Villa Scassi Hos-
pital, Genua; and §§Medical Oncology, S. Eugenio Hospital, Rome, Italy
Tumor angiogenesis is an essential and complex process necessary for the
growth of all tumors and therefore constitutes a potential target of therapy.
Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF)
(Bevacizumab, Avastin, Roche) or their receptors (tyrosine kinase inhibitors,
TKI) have been approved by the Food and Drug Administration. In thymic
epithelial tumors (TET), targeted therapies have been sporadically applied. To
ascertain the presence of potential therapeutic targets, we have analyzed the
expression of VEGF-A, VEGF-C, VEGF-D, and of their TK receptors R1, R2,
and R3 in thymic epithelial tumors (TET) by immunohistochemistry. Platelet-
derived growth factor receptor- (PDGFR-) was also included in this list
because it is another pro-angiogenic TK receptor that can be inhibited by
available TKI (e.g., Sorafenib and Sunitinib). Methodologically, we have ar-
ranged in tissue micro arrays (TMA) duplicate samples from 200 primary TET
collected for a retrospective study sponsored by the Italy-US Program (US- and
Italian-NIH) for Rare Diseases. This series comprised 53 cases (26.5%) of
“benign” histotypes (A, AB, micronodular thymoma [MNT]), 31 cases (15.5%)
of B1 low-malignant TET, 100 cases (50%) of B2/B3 TET (intermediate
malignancy), and 16 (8%) cases of thymic carcinoma (Ca). Results (Table 1) are
TABLE 1.
Histotype VEGFR-1 VEGFR-2 VEGFR-3 VEGF-A VEGF-C VEGF-D PDGFR- AVASTIN
All cases 75.0 (78.0) 87.1 (74.5) 67.0 (52.0) 86.5 (31.0) 86.0 (15.0) 77.8 (5.0) 71.3 (31.0) 59.5 (37.0)
A, AB, MNT, and B1 66.3 (63.0) 84.3 (59.0) 62.7 (44.5) 81.9 (68.0) 79.7 (63.0) 67.9 (42.0) 69.0 (31.0) 55.4 (49.5)
B2, B3, and Carcinoma 81.7 (89.0) 89.1 (82.0) 70.9 (54.5) 89.9 (73.5) 90.7 (71.0) 85.2 (52.0) 73.0 (31.0) 62.5 (32.0)
Carcinoma 85.7 (74.5) 78.6 (66.0) 100 (44.5) 100 (67.0) 93.3 (77.0) 80.0 (76.5) 86.7 (26.0) 73.3 (7.0)
FIGURE 2. Overall survival.
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reported as percentages of positive tumors (tumor containing 0% of immuno-
stained tumor cells). Median values of expression are shown in brackets. To
evaluate the reactivity of Avastin, tumor sections were stained with this antibody
after biotinylation.
The coexpression in epithelial cells of growth factors and their receptors
suggests the presence of autocrine mechanisms in TET. According to
preliminary data, in relapsing/metastatizing tumors, marker expression pat-
tern changes during progression. TET expresses potential targets (to be
validated as predictive) of antiangiogenesis drugs. The comparative low
reactivity of the therapeutic antibody, Avastin, when compared with anti-
VEGF-A antibodies is another example underlying the need for the stan-
dardization of target assessment in terms of reagents and procedures.
Computed Tomography Findings Predicting Invasiveness of
Thymoma
Edith M. Marom, Miguel A. Milito, Cesar A. Moran, Ping Liu, Edward S.
Kim, and Stephen G. Swisher Department of Diagnostic Radiology, Pathol-
ogy, Medical Oncology and Thoracic Surgery, The University of Texas M. D.
Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.
Purpose: To identify the computed tomography (CT) findings that correlate
with thymoma invasiveness before surgical resection.
Methods: We retrospectively reviewed the CT scans of 57 consecutive patients
referred to our institution for thymoma who were surgically treated between
April 30, 1996, and March 4, 2008. Chest CT findings documented were size and
volume of primary tumor; the presence of calcifications, heterogeneity of tumor,
border margination, lobulation, fat plane surrounding tumor, abutment of heart
or great vessels; and the presence of adjacent pulmonary changes. The 2 or
Mantel-Haenszel exact test was used to test the association between categorical
variables at CT and pathologic Masaoka staging.
Results: There were 26 (46%) men, age 17 to 77 years (mean age, 52.7
years). Masoakoa Pathologic Stage: stage I (n  8, 14%), stage IIa (n  18,
31.5%), stage IIb (n  10, 17.5%), stage III (n  12, 21%), and stage IVa
(n  9, 16%). Average tumor size was 8.1 cm (range, 2.5–20 cm). Tumor
size could distinguish stage III and IV from stage I and II (p  0.02) but
could not separate stage I or stage I and IIb from higher stages. Stage I and
II could also be distinguished from higher stages by tumor homogeneity,
border, lobulation, fat infiltration, and50% abutment of vessels (p 0.02).
Stage I and IIb could be distinguished from higher stage by border margin-
ation (p  0.002) and 50% abutment of vessels (p  0.02).
Conclusion: Imaging can differentiate between stage I to II and stage III to
IV disease.
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